IMMUNITYBIO, INC. Comprehensive Income
IMMUNITYBIO, INC. (IBRX) reported Comprehensive Income of -$230.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-04
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$230.55M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$634.28M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$37.98M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$74.82M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$323.64M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$412.38M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$583.37M.
- IMMUNITYBIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$416.39M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$230.55M 10-Q · filed 2026-08-04 | -$864.83M 10-Q · filed 2026-08-04 | -$902.82M derived: sum of 3 quarters · filed 2026-08-04 | -$977.64M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | -$634.28M 10-Q · filed 2026-05-07 | -$672.27M derived: sum of 2 quarters · filed 2026-05-07 | -$747.09M derived: sum of 3 quarters · filed 2026-05-07 | -$847.04M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | -$37.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$112.81M derived: sum of 2 quarters · filed 2026-02-23 | -$212.75M derived: sum of 3 quarters · filed 2026-08-04 | -$323.64M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | -$74.82M 10-Q · filed 2025-11-05 | -$174.77M derived: sum of 2 quarters · filed 2026-08-04 | -$285.65M 10-Q · filed 2025-11-05 | -$343.72M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | -$99.94M 10-Q · filed 2026-08-04 | -$210.83M 10-Q · filed 2026-08-04 | -$268.90M derived: sum of 3 quarters · filed 2026-08-04 | -$354.52M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | -$110.89M 10-Q · filed 2026-05-07 | -$168.96M derived: sum of 2 quarters · filed 2026-05-07 | -$254.57M derived: sum of 3 quarters · filed 2026-05-07 | -$389.14M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$58.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$143.69M derived: sum of 2 quarters · filed 2026-02-23 | -$278.25M derived: sum of 3 quarters · filed 2026-02-23 | -$412.38M 10-K · filed 2026-02-23 | |||
| 2024-09-30 | -$85.62M 10-Q · filed 2025-11-05 | -$220.18M derived: sum of 2 quarters · filed 2025-11-05 | -$354.31M 10-Q · filed 2025-11-05 | -$588.48M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | -$134.56M 10-Q · filed 2025-08-05 | -$268.69M 10-Q · filed 2025-08-05 | -$502.87M derived: sum of 3 quarters · filed 2026-02-23 | -$597.62M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | -$134.13M 10-Q · filed 2025-05-12 | -$368.30M derived: sum of 2 quarters · filed 2026-02-23 | -$463.05M derived: sum of 3 quarters · filed 2026-02-23 | -$600.94M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | -$234.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$328.92M derived: sum of 2 quarters · filed 2026-02-23 | -$466.81M derived: sum of 3 quarters · filed 2026-02-23 | -$583.37M 10-K · filed 2026-02-23 | |||
| 2023-09-30 | -$94.75M 10-Q · filed 2024-11-12 | -$232.64M derived: sum of 2 quarters · filed 2024-11-12 | -$349.19M 10-Q · filed 2024-11-12 | -$457.04M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-06-30 | -$137.89M 10-Q · filed 2024-08-12 | -$254.44M 10-Q · filed 2024-08-12 | -$362.29M derived: sum of 3 quarters · filed 2025-03-03 | -$473.31M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-03-31 | -$116.56M 10-Q · filed 2024-05-09 | -$224.40M derived: sum of 2 quarters · filed 2025-03-03 | -$335.42M derived: sum of 3 quarters · filed 2025-03-03 | -$429.75M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2022-12-31 | -$107.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$218.86M derived: sum of 2 quarters · filed 2025-03-03 | -$313.19M derived: sum of 3 quarters · filed 2025-03-03 | -$416.39M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | -$111.02M 10-Q · filed 2023-11-09 | -$205.35M derived: sum of 2 quarters · filed 2023-11-09 | -$308.55M 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | -$94.33M 10-Q · filed 2023-08-08 | -$197.53M 10-Q · filed 2023-08-08 | |||||
| 2021-12-31 | -$346.91M 10-K · filed 2024-03-19 | ||||||
| 2021-03-31 | -$79.77M 10-Q · filed 2021-05-14 | -$241.15M derived: sum of 2 quarters · filed 2021-05-14 | -$262.95M derived: sum of 3 quarters · filed 2021-05-14 | -$283.01M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2020-12-31 | -$161.38M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | -$183.17M derived: sum of 2 quarters · filed 2021-04-22 | -$203.24M derived: sum of 3 quarters · filed 2021-04-22 | -$221.64M 8-K/A · filed 2021-04-22 | -$92.40M 10-K · filed 2021-03-04 | ||
| 2020-09-30 | -$21.79M 10-Q · filed 2020-11-09 | -$41.86M derived: sum of 2 quarters · filed 2020-11-09 | -$60.26M 10-Q · filed 2020-11-09 | -$186.56M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2020-06-30 | -$20.06M 10-Q · filed 2020-08-07 | -$38.47M 10-Q · filed 2020-08-07 | -$164.77M derived: sum of 3 quarters · filed 2021-05-14 | -$180.32M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2020-03-31 | -$36.99M 10-Q · filed 2021-05-14 | -$18.41M 10-Q · filed 2020-05-11 | -$144.71M derived: sum of 2 quarters · filed 2021-05-14 | -$160.26M derived: sum of 3 quarters · filed 2021-05-14 | -$176.82M derived: sum of 4 quarters · filed 2021-05-14 | ||
| 2019-12-31 | -$107.72M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | -$123.27M derived: sum of 2 quarters · filed 2021-04-22 | -$139.83M derived: sum of 3 quarters · filed 2021-04-22 | -$157.65M 8-K/A · filed 2021-04-22 | -$65.63M 10-K · filed 2020-03-25 | ||
| 2019-09-30 | -$15.55M 10-Q · filed 2020-11-09 | -$32.11M derived: sum of 2 quarters · filed 2020-11-09 | -$49.93M 10-Q · filed 2020-11-09 | -$67.19M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-06-30 | -$16.56M 10-Q · filed 2020-08-07 | -$34.38M 10-Q · filed 2020-08-07 | -$51.64M derived: sum of 3 quarters · filed 2021-03-04 | -$75.18M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-03-31 | -$17.82M 10-Q · filed 2020-05-11 | -$35.08M derived: sum of 2 quarters · filed 2021-03-04 | -$58.62M derived: sum of 3 quarters · filed 2021-03-04 | -$86.24M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2018-12-31 | -$17.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$40.79M derived: sum of 2 quarters · filed 2021-03-04 | -$68.42M derived: sum of 3 quarters · filed 2021-03-04 | -$96.11M 10-K · filed 2021-03-04 | |||
| 2018-09-30 | -$23.54M 10-Q · filed 2019-11-05 | -$51.16M derived: sum of 2 quarters · filed 2019-11-05 | -$78.85M 10-Q · filed 2019-11-05 | -$103.23M derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2018-06-30 | -$27.63M 10-Q · filed 2019-08-06 | -$55.32M 10-Q · filed 2019-08-06 | -$79.70M derived: sum of 3 quarters · filed 2020-03-25 | -$103.63M derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2018-03-31 | -$27.69M 10-Q · filed 2019-05-08 | -$52.08M derived: sum of 2 quarters · filed 2020-03-25 | -$76.01M derived: sum of 3 quarters · filed 2020-03-25 | -$99.74M derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2017-12-31 | -$24.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$48.32M derived: sum of 2 quarters · filed 2020-03-25 | -$72.05M derived: sum of 3 quarters · filed 2020-03-25 | -$96.52M 10-K · filed 2020-03-25 | |||
| 2017-09-30 | -$23.93M 10-Q · filed 2018-11-07 | -$47.67M derived: sum of 2 quarters · filed 2018-11-07 | -$72.14M 10-Q · filed 2018-11-07 | -$96.80M derived: sum of 4 quarters · filed 2019-03-13 | |||
| 2017-06-30 | -$23.73M 10-Q · filed 2018-08-06 | -$48.20M 10-Q · filed 2018-08-06 | -$72.86M derived: sum of 3 quarters · filed 2019-03-13 | -$105.05M derived: sum of 4 quarters · filed 2019-03-13 | |||
| 2017-03-31 | -$24.47M 10-Q · filed 2018-05-07 | -$49.13M derived: sum of 2 quarters · filed 2019-03-13 | -$81.31M derived: sum of 3 quarters · filed 2019-03-13 | -$115.20M derived: sum of 4 quarters · filed 2019-03-13 | |||
| 2016-12-31 | -$24.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$56.84M derived: sum of 2 quarters · filed 2019-03-13 | -$90.73M derived: sum of 3 quarters · filed 2019-03-13 | -$120.90M 10-K · filed 2019-03-13 | |||
| 2016-09-30 | -$32.19M 10-Q · filed 2017-11-07 | -$66.08M derived: sum of 2 quarters · filed 2017-11-07 | -$96.24M 10-Q · filed 2017-11-07 | -$123.26M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-06-30 | -$33.89M 10-Q · filed 2017-08-07 | -$64.06M 10-Q · filed 2017-08-07 | -$91.07M derived: sum of 3 quarters · filed 2018-03-12 | -$137.38M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-03-31 | -$30.17M 10-Q · filed 2017-05-08 | -$30.14M 10-Q · filed 2016-05-16 | -$57.18M derived: sum of 2 quarters · filed 2018-03-12 | -$103.49M derived: sum of 3 quarters · filed 2018-03-12 | -$234.39M derived: sum of 4 quarters · filed 2018-03-12 | ||
| 2015-12-31 | -$27.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$73.33M derived: sum of 2 quarters · filed 2018-03-12 | -$204.22M derived: sum of 3 quarters · filed 2018-03-12 | -$237.07M 10-K · filed 2018-03-12 | |||
| 2015-09-30 | -$46.31M 10-Q · filed 2016-11-10 | -$42.70M 10-Q · filed 2015-11-12 | -$177.21M derived: sum of 2 quarters · filed 2016-11-10 | -$210.05M 10-Q · filed 2016-11-10 | -$160.10M 10-Q · filed 2015-11-12 | -$212.79M derived: sum of 4 quarters · filed 2017-03-15 | |
| 2015-06-30 | -$130.89M 10-Q · filed 2016-08-15 | -$163.74M 10-Q · filed 2016-08-15 | -$166.48M derived: sum of 3 quarters · filed 2017-03-15 | -$167.37M derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2015-03-31 | -$32.85M 10-Q · filed 2016-05-16 | -$35.58M derived: sum of 2 quarters · filed 2017-03-15 | -$36.48M derived: sum of 3 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | -$2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$3.63M derived: sum of 2 quarters · filed 2017-03-15 | -$6.18M 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | -$896.00K 10-Q · filed 2015-11-12 | -$3.45M 10-Q · filed 2015-11-12 | |||||
| 2013-12-31 | -$2.05M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |